Figure 1
Time to progression and overall survival of NLPHL patients on rituximab. (A). Kaplan-Meier analysis of time to progression for 8 of 15 NLPHL patients. (B) Kaplan-Meier analysis of overall survival for 14 of 15 NLPHL patients.
Time to progression and overall survival of NLPHL patients on rituximab. (A). Kaplan-Meier analysis of time to progression for 8 of 15 NLPHL patients. (B) Kaplan-Meier analysis of overall survival for 14 of 15 NLPHL patients.
